Article
Cell & Tissue Engineering
Ying Yang, Ming Zhang, Mengqi Li, Yingchun Li, Wei Yang, Zhuogang Liu, Hongtao Wang
Summary: This study found that adding an unrelated umbilical cord blood unit to haploidentical hematopoietic stem cell transplantation can improve the prognosis and enhance the graft versus leukemia effect without increasing the incidence of graft versus host disease.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Biophysics
Alice Pievani, Valentina Granata, Giacomo Desantis, Laura Antolini, Sara Ornaghi, Antonio Galleu, Andrea Biondi, Bernhard Gentner, Francesco Dazzi, Marta Serafini
Summary: Monocytes are effective at improving engraftment in HSPC transplantation, particularly in cases of limited cell doses such as CB transplantation and HSC gene therapy. Co-culturing monocytes increases survival and stemness of CB-CD34(+) cells. Soluble factors and direct-cell contact interactions play critical roles in the HSC-monocyte crosstalk.
BONE MARROW TRANSPLANTATION
(2022)
Article
Cell & Tissue Engineering
Sara Bucar, Andre Dargen de Matos Branco, Marcia F. Mata, Joao Coutinho Milhano, Iris Caramalho, Joaquim M. S. Cabral, Ana Fernandes-Platzgummer, Claudia L. da Silva
Summary: The study compared the capacity of MSC from different sources to expand UCB CD34(+) cells ex vivo, with AT-derived MSC showing superior expansion potential and maintenance of primitive cells. UCM-derived MSC demonstrated inferior hematopoietic supportive capacity compared to MSC from adult tissues. Further research is needed to determine the impact of HPL on the hematopoietic supportive capacity of MSC.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Takenobu Nii, Katsuhiro Konno, Masaki Matsumoto, Kanit Bhukhai, Suparerk Borwornpinyo, Kazuhiro Sakai, Suradej Hongeng, Daisuke Sugiyama
Summary: The bioactive peptide SL-13R has been developed to promote the expansion of umbilical cord blood CD34+ cells in vitro, showing significant increases in cell numbers and long-term reconstitution ability. The interaction of SL-13R with specific genes AHNAK, ANXA2, and PLEC suggests potential clinical applications for SL-13R in the future.
Article
Genetics & Heredity
Mohammad Reza Mahdavi, Seyed Ehsan Enderami
Summary: This study aimed to expand CD 133+ stem cells derived from UCB on a 3D silk scaffold, showing that the electrospun silk scaffold could be used as a suitable substrate for UCB CD 133+ stem cell expansion.
Article
Biochemistry & Molecular Biology
Ximena Bonilla, Ana Milena Lara, Manuela Llano-Leon, David A. Lopez-Gonzalez, David G. Hernandez-Mejia, Rosa Helena Bustos, Bernardo Camacho-Rodriguez, Ana-Maria Perdomo-Arciniegas
Summary: Umbilical cord blood is an important source of hematopoietic stem and progenitor cells, and recent research has focused on developing ex vivo expansion strategies for these cells. Co-culturing the cells with specific mesenchymal stromal cells has been found to significantly increase their cellular dose and regulate their proliferation capacity. Additionally, the secretory profile of umbilical cord blood-derived cells closely resembles that of bone marrow-derived cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell & Tissue Engineering
Gabriela Sanchez-Petitto, Katayoun Rezvani, May Daher, Hind Rafei, Partow Kebriaei, Elizabeth J. Shpall, Amanda Olson
Summary: Umbilical cord blood transplantation is an attractive alternative source of hematopoietic stem cells, with unique immune tolerance and engraftment kinetics. It has a lower risk of GvHD and comparable clinical outcomes to bone marrow transplantation. However, limitations in cell numbers and delayed engraftment pose challenges for its wider application. Research is being conducted to address these limitations and explore the potential of cord blood in treating various disorders.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Hematology
Isabel C. Yoon, Nicholas A. Bascou, Michele D. Poe, Paul Szabolcs, Maria L. Escolar
Summary: HSCT can prolong the lifespan and improve the functional abilities of late-infantile patients with Krabbe disease, especially those who undergo transplantation before symptom onset. The cognitive outcomes were better for patients with disease onset at >12 months compared to untreated patients. The findings support reclassifying late-infantile Krabbe disease to symptom onset at 12 to 36 months of age.
Article
Hematology
Hao Wang, Kristin N. Berger, Elizabeth L. Miller, Wei Fu, Larisa Broglie, Frederick D. Goldman, Heiko Konig, Su Jin Lim, Arthur S. Berg, Julie-An Talano, Melanie A. Comito, Sherif S. Farag, Jeffrey J. Pu
Summary: This study evaluated the impact of total body irradiation (TBI) on umbilical cord blood transplantation (UCBT) outcomes. The results showed that TBI can improve overall survival and progression-free survival in one condition of UCBT, but no significant differences in the other condition.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2023)
Article
Hematology
Kristin M. Page, Margie A. Ream, Hemalatha G. Rangarajan, Rafael Galindo, Ali Y. Mian, Mai-Lan Ho, James Provenzale, Kathryn E. Gustafson, Jennifer Rubin, Shalini Shenoy, Joanne Kurtzberg
Summary: Infantile Krabbe disease can be effectively treated with hematopoietic cell transplantation if done during the first weeks of life. Newborn screening has facilitated early diagnosis and streamlined treatment referrals for this disease. A retrospective review of six infants diagnosed through newborn screening and treated with hematopoietic cell transplantation showed successful engraftment and improved neurodevelopmental outcomes. All infants are alive and deriving benefits from the timely treatment.
Review
Cell & Tissue Engineering
Elisha Purcell, Timothy Nguyen, Madeleine Smith, Tayla Penny, Madison C. B. Paton, Lindsay Zhou, Graham Jenkin, Suzanne L. Miller, Courtney A. McDonald, Atul Malhotra
Summary: This study systematically reviewed the effects of UCBCs on brain outcomes in animal models of perinatal brain injury. It found differential benefits of UCBCs across different subgroups, such as greater efficacy in IVH model compared to HI model, UCB-MSCs compared to UCB-MNCs, and local administrative routes compared to systemic routes. However, the study identified a serious risk of bias and overall low certainty of evidence.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Cell Biology
Hal E. Broxmeyer, Larry L. Luchsinger, Rona Singer Weinberg, Alexandra Jimenez, Emeline Masson Frenet, Wouter vant Hof, Maegan L. Capitano, Christopher D. Hillyer, Mark H. Kaplan, Scott Cooper, James Ropa
Summary: Long-term cryopreserved cord blood units retain similar numbers of hematopoietic stem and progenitor cells compared with fresh and recently cryopreserved units, and contain highly functional cells. These units demonstrate robust engraftment in mouse transplantation models, and gene program differences can potentially serve as markers for engraftment.
CELL REPORTS MEDICINE
(2023)
Article
Hematology
Satoshi Yamasaki, Shohei Mizuno, Makoto Iwasaki, Sachiko Seo, Naoyuki Uchida, Miyakoshi Shigesaburo, Nobuaki Nakano, Kazuya Ishiwata, Yasufumi Uehara, Tetsuya Eto, Ken Takase, Toshiro Kawakita, Masatsugu Tanaka, Masashi Sawa, Yuta Katayama, Yuichiro Nawa, Onizuka Makoto, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda, Masamitsu Yanada
Summary: This study analyzed the applications and factors affecting unrelated donor bone marrow transplantation (UR-BMT), unrelated donor cord blood stem cell transplantation (UR-CBT), and haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT) in older patients with acute myeloid leukemia (AML) in Japan. The results showed that overall survival (OS) was superior in the UR-BMT group compared to the other groups. However, in non-complete remission (non-CR) patients, Karnofsky performance status (KPS) <80 at HCT and poor-risk cytogenetics were identified as independent predictors of worse OS. Therefore, KPS <80 may serve as an alternative indicator for non-CR AML patients with poor-risk cytogenetics in the selection of HCT, alternative treatments, or best supportive therapy, and optimal KPS is crucial for the success of HCT.
ANNALS OF HEMATOLOGY
(2023)
Article
Cell & Tissue Engineering
Christoph Schaniel, Luena Papa, Marcia L. Meseck, Manisha Kintali, Mansour Djedaini, Mahtab Zangui, Camelia Iancu-Rubin, Ronald Hoffman
Summary: The study demonstrates the feasibility of cryopreserving VPA-expanded stem cell grafts derived from UCB-CD34+ cells for clinical utilization under cGMP. The cryopreserved expanded grafts showed high viability, retention of HSPC phenotypic subtypes, and long-term multilineage repopulation capacity in immunocompromised mice, with comparable cellular and functional parameters to fresh expanded products.
Review
Biology
Hany Elmariah, Claudio G. Brunstein, Nelli Bejanyan
Summary: Allogeneic HCT is the only potential curative therapy for hematologic diseases, but patients are profoundly immunocompromised initially. Immune reconstitution after HCT, especially with alternative donors like haploidentical and umbilical cord blood, can improve access to treatment. Despite challenges, interventions such as antimicrobial prophylaxis and graft manipulation are available to mitigate risks during the immunocompromised period.